[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, Cavaliere F, Kusamura S, Gronchi A, Lise M: Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer; 2004 May 1;100(9):1943-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients.
  • BACKGROUND: Abdominal sarcomatosis is a rare nosologic entity with a poor prognosis.
  • After a Phase I study on cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy (HIIC), the authors reported the results of the treatment of 60 patients using this novel multimodal approach.
  • The median time to local disease progression and the median overall survival were 22 months and 34 months, respectively.
  • CONCLUSIONS: Although these results were encouraging, there was no definitive conclusion reached regarding the therapeutic activity of this locoregional treatment.
  • In the absence of effective systemic agents, the therapeutic potential of cytoreductive surgery plus HIIC should be explored further in comparative trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / mortality. Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Adolescent. Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Intraoperative Care / methods. Laparotomy / methods. Male. Middle Aged. Multivariate Analysis. Prospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15112276.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Rossi CR, Foletto M, Mocellin S, Pilati P, De SM, Deraco M, Cavaliere F, Palatini P, Guasti F, Scalerta R, Lise M: Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer; 2002 Jan 15;94(2):492-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.
  • BACKGROUND: Hyperthermic intraperitoneal intraoperative chemotherapy (HIIC) combined with cytoreductive surgery (CS) has been proposed as a new multimodal treatment mainly for carcinomatosis of gastrointestinal origin.
  • To evaluate whether this regimen could be used for other tumor types, the authors conducted a Phase I study on HIIC with doxorubicin and cisplatin in patients with peritoneal carcinomatosis or sarcomatosis.
  • PATIENTS AND METHODS: Thirty-one patients with peritoneal carcinomatosis or sarcomatosis (PCS) were enrolled for the study.
  • After completion of CS, HIIC was administered with drug doses that were increased for each consecutive cohort following a three-patient cohort scheme.
  • Drug pharmacokinetics and procedure costs also were analyzed.
  • The perfusate/plasma area under the curve ratios were favorable for both drugs, at 162+/-113 and 20.6+/-6.0, respectively, for doxorubicin and cisplatin.
  • Doxorubicin levels in the peritoneum were higher than in tumor or normal tissue samples.
  • CONCLUSIONS: Cytoreductive surgery combined with HIIC is an expensive but feasible therapeutic approach for locally advanced abdominal tumors.
  • Because our preliminary findings for local disease control are encouraging, a Phase II study is now advisable to verify the activity of this promising treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Hyperthermia, Induced. Peritoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Costs and Cost Analysis. Doxorubicin / administration & dosage. Female. Humans. Infusions, Parenteral. Intraoperative Care. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11900234.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Busch TM, Hahn SM, Wileyto EP, Koch CJ, Fraker DL, Zhang P, Putt M, Gleason K, Shin DB, Emanuele MJ, Jenkins K, Glatstein E, Evans SM: Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin Cancer Res; 2004 Jul 15;10(14):4630-8
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients.
  • PURPOSE: Response to photodynamic therapy depends on adequate tumor oxygenation as well as sufficient accumulation of photosensitizer in the tumor.
  • The goal of this study was to investigate the presence of hypoxia and retention of the photosensitizer Photofrin in the tumors of patients with intra-abdominal carcinomatosis or sarcomatosis.
  • In separate tumor nodules from 10 patients, Photofrin uptake was measured by fluorescence after tissue solubilization.
  • Three patients with severely hypoxic tumor nodules exhibited moderate levels of Photofrin uptake of 3.9 +/- 0.4 to 3.9 +/- 0.5 ng/mg (mean +/- SE).
  • The four patients with tumors of physiological oxygenation did not consistently exhibit high tumor concentrations of Photofrin: mean +/- SE drug uptake among these patients ranged from 0.6 +/- 0.8 to 5.8 +/- 0.5 ng/mg.
  • CONCLUSIONS: Carcinomatosis or sarcomatosis of the i.p. cavity may exhibit severe tumor hypoxia.
  • These data emphasize the need for reconsideration of the generally accepted paradigm of small tumor size, good oxygenation, and good drug delivery because this may vary on an individual tumor basis.
  • [MeSH-minor] Appendiceal Neoplasms / metabolism. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / therapy. Benzimidazoles / chemistry. Binding, Competitive / drug effects. Carbocyanines / chemistry. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Female. Gastrointestinal Stromal Tumors / metabolism. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / therapy. Humans. Hydrocarbons, Fluorinated / chemistry. Hydrocarbons, Fluorinated / metabolism. In Vitro Techniques. Intestine, Small / metabolism. Intestine, Small / pathology. Male. Microscopy, Fluorescence. Oxygen / pharmacology. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15269134.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA75285; United States / NCI NIH HHS / CA / CA85831; United States / NCI NIH HHS / CA / CA87971; United States / NCRR NIH HHS / RR / M01-RR0040
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; 0 / Benzimidazoles; 0 / Carbocyanines; 0 / Hydrocarbons, Fluorinated; 0 / cyanine dye 3; 23491-52-3 / HOE 33342; 30DKA3Q1HL / Etanidazole; 97067-70-4 / Dihematoporphyrin Ether; S88TT14065 / Oxygen
  •  go-up   go-down


Advertisement
4. Griffin GM, Zhu T, Solonenko M, Del Piero F, Kapakin A, Busch TM, Yodh A, Polin G, Bauer T, Fraker D, Hahn SM: Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model. Clin Cancer Res; 2001 Feb;7(2):374-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model.
  • Intraperitoneal photodynamic therapy (IP PDT) is an experimental cancer treatment in clinical development for the treatment of peritoneal carcinomatosis and sarcomatosis.
  • A canine study of motexafin lutetium (Lu-Tex)-mediated IP PDT was performed to evaluate normal tissue toxicities of this treatment in the presence and absence of a bowel resection and to assess the feasibility of measuring Lu-Tex fluorescence in abdominal tissues.
  • Laparoscopy was performed 7-10 days after the procedure to assess acute toxicities.
  • In situ fluorescence spectra were obtained from various abdominal tissues before and after light delivery using a fiber array probe with fixed-source detector distances.
  • Lu-Tex-mediated IP PDT was well tolerated at the doses of drug and light studied.
  • Bowel toxicity was not observed in animals treated with a bowel resection before PDT.
  • Analysis of the fluorescence spectra from intra-abdominal tissues suggests that measurements of Lu-Tex in situ are feasible and may provide a way of assessing photosensitizer concentration in vivo without the need for a biopsy.
  • [MeSH-minor] Abdomen / pathology. Animals. Dogs. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Injections, Intraperitoneal. Kidney / drug effects. Kidney / pathology. Laparoscopy. Necrosis. Neoplasms / drug therapy. Neoplasms / pathology. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11234893.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / Photosensitizing Agents; 0A85BJ22L6 / motexafin lutetium; 6433A42F4F / motexafin gadolinium
  •  go-up   go-down


5. Lim SJ, Cormier JN, Feig BW, Mansfield PF, Benjamin RS, Griffin JR, Chase JL, Pisters PW, Pollock RE, Hunt KK: Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol; 2007 Aug;14(8):2309-18
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
  • BACKGROUND: Treatment of peritoneal recurrence following surgical resection of intra-abdominal sarcomas presents a significant challenge to clinicians.
  • Historically, treatment with systemic chemotherapy has been ineffective and surgical resection alone has not been durable.
  • We prospectively evaluated the feasibility of cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin (CDDP) alone or in combination with mitoxantrone (MITOX) for the treatment of sarcomatosis.
  • Eligible patients with evidence of sarcomatosis underwent cytoreductive surgery followed by HIPEC.
  • In the first trial, CDDP dosing was established as 90 mg/m2 with a perfusate time of 90 minutes and temperature of 41 degrees C.
  • CONCLUSIONS: Although the HIPEC technique is feasible for patients with sarcomatosis, it is associated with significant toxicity and limited clinical benefit.
  • [MeSH-major] Antineoplastic Agents / toxicity. Cisplatin / toxicity. Hyperthermia, Induced. Mitoxantrone / toxicity. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Sarcoma / drug therapy. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion / methods. Clinical Trials, Phase I as Topic. Combined Modality Therapy. Disease-Free Survival. Drug Therapy, Combination. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Quality of Life. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541691.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Bonvalot S, Vanel D, Terrier P, Robert C, Le Cesne A, Le Péchoux C: [Management of recurrent soft tissue sarcoma of the retroperitoneum]. Bull Cancer; 2004 Nov;91(11):845-52
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of recurrent soft tissue sarcoma of the retroperitoneum].
  • [Transliterated title] Traitement des récidives des sarcomes rétro-péritonéaux.
  • Complete resection of the lesion and surgical margins status are the only therapeutic factors significantly associated with local control.
  • Further outcome improvements need multimodal therapy since prognosis of these recurrences is poor with lower rates of complete resection and higher grade of malignancy than primary.
  • External beam radiotherapy (EBRT), eventually associated with a boost of intra-operative electron beam radiotherapy (IORT) could improve the outcome in these patients.
  • Chemotherapy protocols may enhance local and systemic outcome and can reduce the volume of high grade tumors and therefore allow a higher rate of complete resection.
  • Isolated pelvic perfusion with local high doses chemotherapy is under investigation.
  • Surgical excision of lung metastases should remain the treatment of choice, if preoperative evaluation indicates that complete clearance of the metastases is possible.
  • Intra-operative chemotherapy after cyto-reductive surgery for the treatment of sarcomatosis is disappointing and complete surgery remains the cornerstone of the treatment with best results for low grade sarcomatosis.
  • Adequate management at the time of primary presentation is likely to afford the best chance for long-term survival.
  • [MeSH-major] Neoplasm Recurrence, Local / therapy. Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Combined Modality Therapy. Humans

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15582888.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 53
  •  go-up   go-down


7. García Sabrido JL, Velasco Sánchez E, Calvo F, Gómez Lanz L, Sánchez Tocino JM, Argudo Garijo S, Ruiz Gómez F, Rodríguez-Bachiller L, González Bayón L, Valdecantos Montes E, Pérez Ferreiroa J: [Intraoperative therapeutic intensification techniques in locally advanced abdominal sarcomas]. Cir Esp; 2006 Oct;80(4):200-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative therapeutic intensification techniques in locally advanced abdominal sarcomas].
  • [Transliterated title] Intensificación terapéutica intraoperatoria en el tratamiento de los sarcomas abdominales localmente avanzados.
  • In this article, we discuss the use of two intraoperative therapeutic intensification techniques, intraoperative radiotherapy (IORT) and hyperthermic intraoperative intraperitoneal chemotherapy (HIIC), in the treatment of locally advanced abdominal sarcomas and peritoneal sarcomatosis.
  • MATERIAL AND METHODS: We analyzed a series of 20 consecutive patients diagnosed with advanced abdominal sarcoma and 5 patients with a diagnosis of peritoneal sarcomatosis who were evaluated and treated in our department from December 1996 to October 2005.
  • In peritoneal sarcomatosis we performed massive cytoreduction followed by HIIC.
  • RESULTS: The survival rate in advanced abdominal sarcomas without sarcomatosis was 65% at 26 months.
  • Among the 5 patients diagnosed with peritoneal sarcomatosis, 3 were alive, and 2 were without recurrence at 20 months of follow-up.
  • Maximal cytoreduction plus HIIC used as treatment of peritoneal sarcomatosis is a feasible technique that offers a therapeutic option with curative intent.
  • [MeSH-major] Abdominal Neoplasms / therapy. Intraoperative Care / methods. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Cancer, Regional Perfusion / methods. Combined Modality Therapy. Female. Humans. Hyperthermia, Induced / methods. Laparotomy / methods. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant / methods. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040669.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Hahn SM, Fraker DL, Mick R, Metz J, Busch TM, Smith D, Zhu T, Rodriguez C, Dimofte A, Spitz F, Putt M, Rubin SC, Menon C, Wang HW, Shin D, Yodh A, Glatstein E: A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res; 2006 Apr 15;12(8):2517-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis.
  • PURPOSE: A previous phase I trial of i.p. photodynamic therapy established the maximally tolerated dose of Photofrin (Axcan Pharma, Birmingham, AL)-mediated photodynamic therapy and showed encouraging efficacy.
  • The primary objectives of this phase II study were to determine the efficacy and toxicities of i.p. photodynamic therapy in patients with peritoneal carcinomatosis and sarcomatosis.
  • The outcomes of interest were (a) complete response, (b) failure-free survival time, and (c) overall survival time.
  • Photosensitizer levels in tumor and normal tissues were measured.
  • Twenty-nine patients did not receive light treatment.
  • All 100 patients had progressed by the time of statistical analysis.
  • CONCLUSIONS: Intraperitoneal Photofrin-mediated photodynamic therapy is feasible but does not lead to significant objective complete responses or long-term tumor control.
  • Heterogeneity in photosensitizer uptake and tumor oxygenation, lack of tumor specificity for photosensitizer uptake, and the heterogeneity in tissue optical properties may account for the lack of efficacy observed.
  • [MeSH-major] Carcinoma / drug therapy. Dihematoporphyrin Ether / therapeutic use. Peritoneal Neoplasms / drug therapy. Photochemotherapy / methods. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Diarrhea / chemically induced. Edema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Sunburn / etiology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638861.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA087971
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


9. Vocelka CR, Anderson DL, Crockett GI: Hyperthermic intraoperative intraperitoneal chemotherapy for peritoneal carcinomatosis and sarcomatosis using a cardioplegia heat exchanger and a two-pump system: a case report. Perfusion; 2000 Nov;15(6):549-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraoperative intraperitoneal chemotherapy for peritoneal carcinomatosis and sarcomatosis using a cardioplegia heat exchanger and a two-pump system: a case report.
  • A 34-year-old male diagnosed with pseudomyxoma peritoneii presented for an exploratory laparotomy and hyperthermic intraoperative intraperitoneal chemotherapy.
  • A circuit using two roller pumps and a cardioplegia administration set was assembled to deliver the chemotherapy perfusate at a consistent temperature.
  • The authors discuss a case in which this treatment modality was used, describing the perfusionist's role and the circuit design.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Carcinoma / surgery. Hyperthermia, Induced / methods. Infusions, Parenteral / instrumentation. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Sarcoma / drug therapy. Sarcoma / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Intraoperative Care / instrumentation. Intraoperative Care / methods. Male. Omentum / pathology. Splenic Neoplasms / drug therapy. Splenic Neoplasms / secondary. Splenic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11131220.001).
  • [ISSN] 0267-6591
  • [Journal-full-title] Perfusion
  • [ISO-abbreviation] Perfusion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol; 2001 Apr;27(3):239-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
  • Peritoneal carcinomatosis, regardless of primary tumour type, has always been a lethal condition.
  • Recently special treatments using cytoreductive surgery with peritonectomy procedures combined with peri-operative intraperitoneal chemotherapy have resulted in long-term survival.
  • Pseudomyxoma peritonei may be especially appropriate for these aggressive local regional treatments.
  • All patients treated prior to 1999 are presented; patients left with gross residual disease after surgery were not given intraperitoneal chemotherapy, but were later treated with intravenous chemotherapy after cytoreduction.
  • The intraperitoneal chemotherapy was given in the peri-operative period, starting with mitomycin C.
  • For patients whose pathology showed adenomucinosis, intraperitoneal chemotherapy was limited to treatment in the operating theatre with heated mitomycin C.
  • The histopathology categorized the patients as adenomucinosis, intermediate type, or mucinous carcinomatosis.
  • Patients with a complete cytoreduction and adenomucinosis by pathology had a 5-year survival of 86%; while hybrid pathology survival at 5 years was 50%.
  • Cytoreductive surgery and peri-operative intraperitoneal chemotherapy is the current standard treatment for selected patients with peritoneal surface spread of appendiceal primary tumours.
  • Similar strategies for other patients with peritoneal surface malignancy such as peritoneal carcinomatosis from colon or gastric cancer, peritoneal sarcomatosis, or peritoneal mesothelioma should be pursued.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Digestive System Surgical Procedures / methods. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Injections, Intraperitoneal. Male. Middle Aged. Mitomycin / administration & dosage. Multivariate Analysis. Probability. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Syndrome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11373099.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Begossi G, Gonzalez-Moreno S, Ortega-Perez G, Fon LJ, Sugarbaker PH: Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Eur J Surg Oncol; 2002 Feb;28(1):80-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma.
  • Despite new developments in multi-modality treatments, complete resection remains as an absolute requirement for cure of gastrointestinal cancer.
  • We have reported benefits from combined treatment with complete cytoreduction and intraperitoneal chemotherapy.
  • This paper describes the current strategy that the surgical oncologist should pursue in the treatment of patients with peritoneal carcinomatosis, sarcomatosis and mesothelioma.
  • Technical details required for this surgery include patient position, incision and exposure, complete lysis of adhesion, electroevaporative dissection with irrigation and suction to preserve the translucent quality of tissues, peritonectomy procedures, proper positioning of tubes and drains for intraperitoneal chemotherapy, and reconstructive surgery.
  • Understanding the treatment and mastery of surgical skills to manage the peritoneal surface spread of cancer has led to long-term survival of selected patients.
  • Combination of this treatment strategy with proper patient selection has reduced the mortality and morbidity.
  • The success of cytoreductive surgery and perioperative intraperitoneal chemotherapy depends on a long-term dedication to achieve the full potential of a curative outcome.
  • Our unit has continued to achieve good results over two decades as improved results of treatment have evolved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / surgery. Mesothelioma / surgery. Peritoneal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Cholecystectomy / methods. Colectomy / methods. Combined Modality Therapy. Electrosurgery. Humans. Hyperthermia, Induced. Peritoneal Lavage. Peritoneum / surgery. Postoperative Complications. Reoperation. Splenectomy / methods

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11869020.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Bonvalot S, Cavalcanti A, Le Péchoux C, Terrier P, Vanel D, Blay JY, Le Cesne A, Elias D: Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. Eur J Surg Oncol; 2005 Oct;31(8):917-23
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis.
  • PURPOSE: In order to decrease loco-regional relapse after complete resection of peritoneal sarcomatosis (PS), the role of intraperitoneal chemotherapy (IPEC) was prospectively evaluated.
  • Primary endpoint was survival, measured as time from randomization to death.
  • The scheduled number of patients needed was 40 in order to detect a minimal increase of 40% overall survival with the adjunction of IPEC with a power of 80%.
  • Ratio of retroperitoneal (RPS) and visceral (VS) sarcomatosis were 9/10 and 6/13 in IPEC- and IPEC+ group, respectively.
  • The median local relapse-free, metastatic relapse-free survival and overall survival were identical in both groups (12.5, 18 and 29 months, respectively), with no difference between RPS and VS sarcomatosis.
  • Complete surgery remains the cornerstone of the treatment of patients with sarcomatosis with best results for low grade sarcomatosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Electrosurgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975759.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Peixoto Callejo I: Peritoneal solitary fibrous tumour (SFT): long-term survival of recurrent and metastasised SFT treated with cytoreductive surgery and intraperitoneal chemotherapy. Clin Transl Oncol; 2009 Apr;11(4):250-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal solitary fibrous tumour (SFT): long-term survival of recurrent and metastasised SFT treated with cytoreductive surgery and intraperitoneal chemotherapy.
  • The patient recurred diffusely, developing a pattern of sarcomatosis and hepatic metastasis and was treated by surgical cytoreduction followed by intraoperative peritoneal hyperthermic chemotherapy (IPHC).
  • Subsequently, he developed pulmonary metastases and was treated with palliative chemotherapy.
  • New treatment strategies for a rare disease such as this one have first to be described in order to improve patient follow-up.
  • [MeSH-major] Liver Neoplasms / mortality. Lung Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / therapy. Solitary Fibrous Tumors / mortality. Solitary Fibrous Tumors / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Hyperthermia, Induced. Male. Surgical Procedures, Operative. Survival Rate. Survivors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):543-59 [14567017.001]
  • [Cites] Lung Cancer. 1999 Jan;23 (1):53-60 [10100146.001]
  • [Cites] Arch Pathol Lab Med. 2006 Feb;130(2):213-6 [16454566.001]
  • [Cites] Cancer J Sci Am. 1999 Jan-Feb;5(1):48-51 [10188061.001]
  • [Cites] Ann Diagn Pathol. 1998 Feb;2(1):19-24 [9845719.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):460-2 [15043457.001]
  • (PMID = 19380303.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, Gronchi A, Deraco M: Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol; 2010 Dec;17(12):3220-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
  • BACKGROUND: Unlike novel molecular-targeted therapies for metastatic gastrointestinal stromal tumors (GIST), conventional treatments for peritoneal sarcomatosis (PS) are mostly ineffective.
  • As with carcinomatosis of epithelial origin, a rationale base supports an aggressive locoregional treatment of PS, but the use of CRS and HIPEC in this setting is still controversial.
  • We assessed the outcome of clinically and pathologically homogeneous subsets of patients with PS uniformly treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • CONCLUSIONS: Overall, results of CRS and HIPEC did not compare favorably to those of conventional therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Leiomyosarcoma / therapy. Peritoneal Neoplasms / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Liposarcoma / classification. Liposarcoma / pathology. Liposarcoma / therapy. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Prospective Studies. Retroperitoneal Neoplasms / classification. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / therapy. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S327. Alessanrdro, Gronchi [corrected to Gronchi, Alessandro]
  • (PMID = 20585874.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; Retroperitoneal liposarcoma
  •  go-up   go-down


15. Rossi CR, Casali P, Kusamura S, Baratti D, Deraco M: The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol; 2008 Sep 15;98(4):291-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The consensus statement on the locoregional treatment of abdominal sarcomatosis.
  • Abdominal sarcomatosis (AS) is a rare condition characterized by soft tissue sarcoma spreading throughout the abdomen, in the absence of extra-abdominal dissemination.
  • Systemic chemotherapy is the standard of care for AS from non-GIST sarcomas, but with an essentially palliative aim and major limitations.
  • Innovative targeted therapies has deeply affected the natural history of GIST, at least in prolonging significantly survival in responsive patients.
  • In this context, the notion that abdominal spread in the lack of extra-peritoneal lesions may typically occur in a number of patients, along with the dismal prognosis generally carried by AS, has prompted a few centers to perform cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • To date, the rarity of these presentations makes it difficult to evaluate the clinical results and the role of combined local-regional treatment is still a matter of debate.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / surgery. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Sarcoma / drug therapy. Sarcoma / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Consensus. Humans. Infusions, Parenteral. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726899.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


16. Bereder I, Guerin O, Boulahssass R, Couderc A, Mailland V, Macone F, Mounier N, Habre J, Karimdjee-Soilihi B, Bereder J: Cytoreductive surgery combined with peritoneal intraoperative heated chemotherapy for management of peritoneal carcinomatosis in 59 adults older than age 65. J Clin Oncol; 2009 May 20;27(15_suppl):e20657

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery combined with peritoneal intraoperative heated chemotherapy for management of peritoneal carcinomatosis in 59 adults older than age 65.
  • Recent success of new approach, combining surgery and intraperitoneal heated chemotherapy (HIPEC) are reported.
  • METHODS: A retrospective study was performed to evaluate toxicity and to identify the principal prognostic indicators with this combined treatment.
  • The principal etiologies of PC in group1 were recurrent ovarian cancer (N=33), colorectal cancer (N=9), peritoneal mesothelioma (N=6), pseudomyxoma (N=9) and sarcomatosis (N=2).
  • No death occurred in post operative course and the procedure related morbidity rate was 10%.
  • CONCLUSIONS: Therapeutic approach combining cytoreductive surgery with HIPEC may achieve long-term survival in a selected group of patients with PC with acceptable mortality and morbidity.
  • For elderly patients, this treatment could be performed in selected cases without frailty.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961621.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Sugarbaker PH: Review of a personal experience in the management of carcinomatosis and sarcomatosis. Jpn J Clin Oncol; 2001 Dec;31(12):573-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of a personal experience in the management of carcinomatosis and sarcomatosis.
  • METHODS: An aggressive approach to peritoneal surface malignancy involves peritonectomy procedures, perioperative intraperitoneal chemotherapy and knowledgeable patient selection.
  • Proper patient selection is mandatory for optimizing the results of treatment.
  • Also, sarcomatosis patients overall had a 40% 5-year survival in selected patients.
  • In all malignancies, early aggressive treatment of minimal peritoneal surface dissemination showed the greatest benefit.
  • Adjuvant phase III studies with perioperative intraperitoneal chemotherapy in diseases where peritoneal surface spread occurs are indicated.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Gastrointestinal Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Humans. Infusions, Parenteral. Mesothelioma / drug therapy. Neoplasm Seeding. Patient Selection. Peritoneum / surgery. Second-Look Surgery. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Jpn J Clin Oncol. 2001 Dec;31(12):571-2 [11902486.001]
  • (PMID = 11902487.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 24
  •  go-up   go-down


18. Bauer TW, Hahn SM, Spitz FR, Kachur A, Glatstein E, Fraker DL: Preliminary report of photodynamic therapy for intraperitoneal sarcomatosis. Ann Surg Oncol; 2001 Apr;8(3):254-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary report of photodynamic therapy for intraperitoneal sarcomatosis.
  • INTRODUCTION: Sarcomatosis is the disseminated intraperitoneal spread of sarcoma.
  • It is a condition for which there is no effective treatment.
  • Photodynamic therapy (PDT) is a cancer treatment modality that uses a photosensitizing agent and laser light to kill cells.
  • We report our preliminary Phase II clinical trial experience using PDT for the treatment of intraperitoneal sarcomatosis.
  • METHODS: From May 1997 to December 1998 eleven patients received twelve PDT treatments for intraperitoneal sarcomatosis.
  • Light therapy was administered at a fluence of 2.5 J/cm2 of 532 nm green light to the mesentery and serosa of the small bowel and colon; 5 J/cm2 of 630 nm red light to the stomach and duodenum; 7.5 J/cm2 of red light to the surface of the liver, spleen, and diaphragms; and 10 J/cm2 of red light to the retroperitoneal gutters and pelvis.
  • Response to treatment was evaluated by abdominal CT scan at 3 and 6 months, diagnostic laparoscopy at 3 to 6 months, and clinical examination every 3 months.
  • CONCLUSIONS: Debulking surgery with intraperitoneal PDT for sarcomatosis is feasible.
  • [MeSH-major] Hematoporphyrin Photoradiation / methods. Peritoneal Neoplasms / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Dihematoporphyrin Ether / adverse effects. Dihematoporphyrin Ether / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Laparotomy. Male. Middle Aged. Pennsylvania / epidemiology. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11314943.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


19. Pilati P, Rossi CR, Mocellin S, Foletto M, Scagnet B, Pasetto L, Lise M: Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol; 2001 Mar;27(2):125-34
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment of peritoneal carcinomatosis and sarcomatosis.
  • Peritoneal carcinomatosis and sarcomatosis (PCS) are short-term fatal conditions amenable only to palliative treatment.
  • They are generally considered as a systemic disease at clinical presentation, and are resistant to standard treatments.
  • Surgical treatment alone, or in combination with systemic chemotherapy, has yielded poor results in terms of survival and quality of life.
  • This may diminish any residual tumour following macroscopic excision and may overcome the pharmacokinetic limits of systemic chemotherapy.
  • A further improvement in this multimodal approach may be achieved by the use of hyperthermic intraperitoneal intraoperative chemotherapy (HIIC).
  • However, series reported in the literature are relatively small and heterogeneous, and clinical and technical factors which include the selection of patients, optimal drugs dosage and temperature, evaluation of outcome and costs are still under discussion.
  • [MeSH-major] Carcinoma / therapy. Peritoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Humans. Hyperthermia, Induced. Neoadjuvant Therapy. Quality of Life. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11289746.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 99
  •  go-up   go-down


20. Gonlugur T, Sapmaz F, Katrancioglu O, Gonlugur U, Elagoz S: Pulmonary lymphangitic sarcomatosis and a review of the literature. Clin Exp Metastasis; 2009;26(5):399-402
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary lymphangitic sarcomatosis and a review of the literature.
  • Pulmonary lymphangitic sarcomatosis is a rare but important manifestation of an angiosarcoma.
  • Optimal treatment of these patients is not well defined, but a trial of chemotherapy may be warranted.
  • [MeSH-major] Lymphatic Diseases / diagnosis. Lymphatic Diseases / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cytoplasm / metabolism. Diagnosis, Differential. Fatal Outcome. Humans. Male. Pelvic Neoplasms / diagnosis. Radiography, Thoracic / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1987 May;111(5):459-63 [3105516.001]
  • [Cites] Radiology. 1988 Mar;166(3):705-9 [3340765.001]
  • [Cites] Arch Pathol Lab Med. 1986 Feb;110(2):112-5 [3753842.001]
  • [Cites] AJR Am J Roentgenol. 1992 Jun;158(6):1217-22 [1590110.001]
  • [Cites] Chest. 1993 Mar;103(3):967-8 [8449110.001]
  • [Cites] Chest. 1976 Jan;69(1):106-8 [1244262.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jan;30(1):37-9 [10770568.001]
  • [Cites] Cancer. 1974 Jun;33(6):1558-63 [4834152.001]
  • [Cites] Chest. 1972 Aug;62(2):179-87 [5050223.001]
  • [Cites] Chest. 1992 Oct;102(4):1113-7 [1327663.001]
  • [Cites] AJR Am J Roentgenol. 1985 Sep;145(3):505-10 [3927666.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jun;131(6):970-3 [17550329.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):825-8 [15350381.001]
  • [Cites] Intern Med. 2007;46(8):491-4 [17443041.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):229-32 [10623714.001]
  • [Cites] J Thorac Imaging. 1985 Dec;1(1):54-64 [3843414.001]
  • [Cites] Respiration. 1998;65(5):406-10 [9782226.001]
  • [Cites] Acta Otolaryngol Suppl. 2004 Oct;(554):71-3 [15513516.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jul;165(1):49-52 [7785630.001]
  • [Cites] Int J Gynecol Cancer. 2002 Mar-Apr;12 (2):208-13 [11975682.001]
  • (PMID = 18506585.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Charney SC, Bergman PJ, McKnight JA, Farrelly J, Novosad CA, Leibman NF, Camps-Palau MA: Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions: A retrospective analysis of 12 cases (1997-2002)*. Vet Comp Oncol; 2005 Dec;3(4):171-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions: A retrospective analysis of 12 cases (1997-2002)*.
  • Abstract Carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions, are difficult to treat and generally carry a poor prognosis.
  • The purpose of this study was two-fold; first, to determine the prognosis for dogs with carcinomatosis, sarcomatosis, or mesothelioma, with or without malignant effusions; second, to evaluate the safety and efficacy of treatment with intracavitary (IC) carboplatin and mitoxantrone in dogs with these syndromes.
  • Seven were untreated and 12 were treated with IC chemotherapy (mitoxantrone and/or carboplatin), and multiple factors were analysed for significance with respect to survival time.
  • The median survival time (MST) for untreated dogs was 25 days, whereas the MST for treated dogs was 332 days (Log Rank, P < 0.0001).
  • Treatment with IC chemotherapy was well tolerated.
  • This study suggests that IC chemotherapy with mitoxantrone and/or carboplatin is an effective treatment for dogs with carcinomatosis, sarcomatosis or mesothelioma, with or without malignant effusion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754772.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH: Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol; 2003 Oct;129(10):549-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
  • PURPOSE: To perform a phase I study of intraperitoneal cis-bis-neodecanoato ( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar vesicles (L-NDDP) for peritoneal carcinomatosis or sarcomatosis.
  • Laparoscopy was performed on the first two courses for evaluation, adhesiolysis, and chemotherapy administration.
  • Afterwards, chemotherapy was administered through a peritoneal catheter.
  • Pharmacokinetics studies indicated a rapid but low absorption of drug into the systemic circulation, with a prolonged retention of platinum in the plasma compartment.
  • Peritoneal L-NDDP exposure was 17 to 49-times greater than in the plasma compartment.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adult. Aged. Area Under Curve. Ascites / metabolism. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / metabolism. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / metabolism. Endometrial Stromal Tumors / drug therapy. Endometrial Stromal Tumors / metabolism. Female. Humans. Injections, Intraperitoneal. Liposomes. Male. Mesothelioma / drug therapy. Mesothelioma / metabolism. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Peritoneum / diagnostic imaging. Peritoneum / metabolism. Radionuclide Imaging. Technetium. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4509-12 [3396003.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(4):315-7 [1879050.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):884-91 [9041149.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2 Suppl 2):17-9; quiz 20, 58 [8202717.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jun;49(6):499-503 [12107555.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Oct;10(4):915-33, xi [11641098.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1950-5 [8960474.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82 [11813623.001]
  • [Cites] J Med Chem. 1991 Jan;34(1):325-9 [1992134.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1237-41 [11948138.001]
  • [Cites] Surg Clin North Am. 1978 Feb;58(1):131-42 [417410.001]
  • [Cites] Anal Biochem. 1987 May 15;163(1):21-6 [3039867.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2961-7 [8523061.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):373-9 [9815694.001]
  • [Cites] Surgery. 1993 Jun;113(6):631-6 [8506520.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(1):1-8 [2720887.001]
  • [Cites] Semin Oncol. 1985 Sep;12(3 Suppl 4):23-8 [4048973.001]
  • [Cites] Dis Colon Rectum. 1993 Apr;36(4):323-9 [8458256.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4254-9 [2364384.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3944-6 [12351590.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2622-9 [8640714.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2048-52 [8156509.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):232-7 [3121165.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1001-7 [11181662.001]
  • [Cites] J Microencapsul. 1994 Jan-Feb;11(1):41-54 [8138874.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):65-71 [2104572.001]
  • (PMID = 14513369.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Organoplatinum Compounds; 113427-19-3 / bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II); 7440-26-8 / Technetium
  •  go-up   go-down


23. Deraco M, Laterza B, Kusamura S, Baratti D: [Updated treatment of peritoneal carcinomas: a review]. Minerva Chir; 2007 Dec;62(6):459-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Updated treatment of peritoneal carcinomas: a review].
  • Examples of diseases that can spread mainly within the peritoneal cavity are appendiceal tumors, ovarian cancer, colorectal cancer, abdominal sarcomatosis, gastric cancer and peritoneal mesothelioma.
  • The locoregional therapy is defined as the combination of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP).
  • The rationale of this combined therapy for PSM is based on the natural history of this clinical entity that remains confined in the peritoneal cavity for most of its natural history.
  • This pattern of spread would seem to indicate the potential usefulness of selectively increasing drug concentration in the tumour-bearing area by direct intraperitoneal chemotherapy instillation.
  • A significant improvement in survival was associated with hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with gastric cancer.
  • Considering the constant increasing of diseases treatable with this procedure, more centres should be activated.
  • The establishment of a clear policy and scientific guidelines is mandatory, in order to perform the CRS+HIPEC safely, minimizing treatment-related morbidity and mortality and maximizing the results in terms of survival and quality of life.
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Critical Care. Female. Humans. Hyperthermia, Induced. Infusions, Parenteral. Injections, Intraperitoneal. Male. Nutritional Support. Patient Selection. Postoperative Care. Postoperative Complications. Quality of Life. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091656.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 71
  •  go-up   go-down


24. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey F, Eilber FR: Recurrent gastrointestinal stromal sarcomas. Surg Oncol; 2000 Aug;9(2):71-5
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite surgical resection with or without adjuvant systemic chemotherapy the vast majority of these patients succumb to intraperitoneal sarcomatosis and/or hepatic metastases.
  • In an attempt to improve upon the morbidity and mortality associated with this disease we and several other centers have begun treating these patients with intraperitoneal chemotherapy.
  • We have found that aggressive surgical resection with postoperative intraperitoneal chemotherapy has significantly lowered the peritoneal recurrence rate in patients with recurrent gastrointestinal stromal sarcomas as compared to those who have undergone surgical resection alone.
  • However, this treatment approach has proven to be ineffective in preventing hepatic metastases, and thus has had little effect upon overall survival.
  • With the treatment of primary rather than recurrent disease we hope to interrupt the disease process at an earlier stage further decreasing peritoneal recurrences and potentially improving survival.
  • [MeSH-major] Gastrointestinal Neoplasms / drug therapy. Mitoxantrone / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Sarcoma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Injections, Intraperitoneal. Liver Neoplasms / secondary. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094326.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


25. Younan R, Kusamura S, Baratti D, Oliva GD, Costanzo P, Favaro M, Gavazzi C, Deraco M: Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol; 2005 Nov;12(11):910-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treated pathologies included peritoneal mesothelioma; pseudomyxoma peritonei; colorectal, ovarian, or gastric carcinomatosis; and abdominal sarcomatosis.
  • On univariate analysis we found a statistically significant association between bowel complications and the following variables: sex, previous systemic chemotherapy status, number of anastomoses ( fewer than two vs. two or more), duration of the procedure (<8.7 vs. >or=8.7 hours), and extent of cytoreduction.
  • After multivariate analysis, male sex (odds ratio [OR], 4.2), no previous systemic chemotherapy (OR, 3.5), and duration of the procedure >or=8.7 hours (OR, 6.3) were considered independent risk factors for bowel complications.
  • Male sex, duration of the procedure, and no previous systemic chemotherapy are independent unfavorable risk factors.
  • [MeSH-major] Hyperthermia, Induced. Intestinal Diseases / etiology. Peritoneal Neoplasms / complications. Peritoneal Neoplasms / therapy. Peritoneum / surgery
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Colon / surgery. Combined Modality Therapy. Female. Gastrectomy. Humans. Intestinal Fistula / etiology. Intestines / surgery. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177862.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


26. Baratti D, Kusamura S, Deraco M: The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. J Surg Oncol; 2008 Sep 15;98(4):258-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combination of cyto-reductive surgery and perioperative intraperitoneal chemotherapy has changed PSM management from palliation to possible cure.
  • Due to the inherent differences in biological and clinical behavior, the optimal adaptation of comprehensive treatment to each PSM is still a matter of debate.
  • A session of "The Fifth International Workshop on Peritoneal Surface Malignancy" (Milan, Italy, December 4-6, 2006) was committed to reach a consensus pertaining to conceptual and technical aspects of the loco-regional treatment of each PSM.
  • A total of 103 international experts from 17 countries were included in six Working Groups (WG) for each of the following PSM: peritoneal mesothelioma, abdominal sarcomatosis, carcinomatosis of gastric, colo-rectal, appendiceal, and ovarian origin.
  • The main conflicting points (CP) regarding preoperative evaluation, patient eligibility, combined treatment methodology, postoperative follow-up and future investigational perspectives were summarized as a list of multiple-choice questions.
  • The general treatment guidelines and future investigational perspectives were defined.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Consensus. Delphi Technique. Humans. Infusions, Parenteral

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726888.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 23
  •  go-up   go-down


27. Hendren SK, Hahn SM, Spitz FR, Bauer TW, Rubin SC, Zhu T, Glatstein E, Fraker DL: Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol; 2001 Jan-Feb;8(1):65-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors.
  • BACKGROUND: Photodynamic therapy (PDT) combines photosensitizer drug, oxygen, and laser light to kill tumor cells on surfaces.
  • This is the initial report of our phase II trial, designed to evaluate the effectiveness of surgical debulking and PDT in carcinomatosis and sarcomatosis.
  • Patients were followed with CT scans and laparoscopy to evaluate responses to treatment.
  • RESULTS: Forty-two patients were adequately debulked at surgery; these comprise the treatment group.
  • Median time to recurrence was 3 months (range, 1-21 months).
  • Deficiencies in photosensitizer delivery, tissue oxygenation, or laser light distribution leading to recurrences may be addressed through the future use of new photosensitizers.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / surgery. Dihematoporphyrin Ether / therapeutic use. Peritoneal Neoplasms / surgery. Photochemotherapy. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11206227.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


28. Cengel KA, Glatstein E, Hahn SM: Intraperitoneal photodynamic therapy. Cancer Treat Res; 2007;134:493-514
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal photodynamic therapy.
  • Peritoneal carcinomatosis and sarcomatosis are generally incurable problems for which there are few good treatment options.
  • Intraperitoneal PDT is potentially an ideal therapy for peritoneal carcinomatosis because of its relatively superficial treatment effect.
  • A Phase II trial of IP PDT with the first generation photosensitizer, Photofrin, demonstrates that this treatment approach is tolerable clinically but is associated with substantial toxicity suggesting a narrow therapeutic index.
  • Correlative studies of photosensitizer uptake in human tumour and normal tissues show little tumour selectivity.
  • This lack of photosensitizer selectivity for tumour in combination with tumour hypoxia (as opposed to oxic normal tissues) is likely a major reason for the narrow therapeutic index of intraperitoneal PDT.
  • However, the advent of novel and potentially molecularly targeted photosensitizers, combined with enhancement of PDT cancer cell cytotoxicity through inhibition of growth factor signaling should greatly improve the therapeutic index of intraperitoneal PDT.
  • In addition, other approaches, including the use of nanotechnology, may allow the administration of fractionated PDT which may also improve the therapeutic index of this treatment.
  • The clinical implementation of these technologies may allow for highly effective and well tolerated treatment of intraperitoneal carcinomatosis with PDT.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy. Photochemotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633077.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 120
  •  go-up   go-down


29. Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer; 2006 Mar 1;106(5):1144-53
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of this prospective Phase II study was to analyze morbidity and mortality of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP) in the treatment of peritoneal surface malignancies.
  • METHODS: A total of 205 patients (50 with peritoneal mesothelioma, 49 with pseudomyxoma peritonei, 41 with ovarian cancer, 32 with abdominal sarcomatosis, 13 with colon cancer, 12 with gastric cancer, and 8 with carcinomatosis from other origins) underwent 209 consecutive procedures.
  • IPHP through the closed abdomen technique was conducted with a preheated (42.5 degrees C) perfusate containing cisplatin + mitomycin C or cisplatin + doxorubicin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Morbidity. Neoplasm Recurrence, Local. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456817.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement